Becton, Dickinson and Co (BDX)
NYSE:BDX
Want to see BDX full AI Analyst Report?
BDX Stock Chart & Stats
$158.54
$1.03(0.44%)
At close: 4:00 PM EST
$158.54
$1.03(0.44%)
Day’s Range― - ―
52-Week Range$141.82 - $213.08
Previous CloseN/A
Volume443.35K
Average Volume (3M)3.23M
Market Cap
$40.68B
Enterprise Value$69.95B
Total Cash (Recent Filing)$816.00M
Total Debt (Recent Filing)$17.28B
Price to Earnings (P/E)―
Beta0.39
Next Earnings
Jul 30, 2026EPS Estimate
3.13Next Dividend Ex-DateN/A
Dividend Yield2.13%
Share Statistics
EPS (TTM)3.95
Shares Outstanding275,540,440
10 Day Avg. Volume3,152,080
30 Day Avg. Volume3,229,172
Financial Highlights & Ratios
PEG Ratio-36.95
Price to Book (P/B)1.66
Price to Sales (P/S)1.93
P/FCF Ratio15.80
Enterprise Value/Market Cap1.72
Enterprise Value/Revenue3.27
Enterprise Value/Gross Profit7.04
Enterprise Value/Ebitda16.80
Forecast
1Y Price Target
$182.20Price Target Upside14.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)12.59
Revenue Forecast (FY)$19.20B
Bulls Say, Bears Say
Bulls Say
Corporate Separation And Capital AllocationCorporate separation into a pure‑play MedTech company with proceeds deployed to reduce debt and accelerate share repurchases should simplify the balance sheet and support shareholder returns, according to analyst updates.
Exposure To Growing Biopharma MarketsStrong exposure to expanding GLP‑1 and biologics markets through prefilled syringes and biopharma systems positions the company to capture rising demand and broaden revenue streams, per analyst notes.
Operational Efficiency And Margin ImprovementManagement's operational efficiency programs and a streamlined manufacturing footprint are expected to support margin improvement and create a foundation for revenue reacceleration, as highlighted by analysts.
Bears Say
Leadership Transition And Execution RiskA transition in the chief financial officer elevates execution risk and increases the focus on delivering consistent revenue growth and earnings, adding uncertainty to the outlook.
Revenue Restatement And Reporting TransparencyA recent revenue restatement and the resulting update to revenue reporting models raises transparency and forecasting concerns that could weigh on investor confidence.
Vaccine And Geographic Revenue HeadwindsDeclining vaccine demand combined with geographic headwinds from China operations is pressuring revenue growth and could reduce the contribution from previously strong product lines.
Becton Dickinson News
BDX FAQ
What was Becton, Dickinson and Co’s price range in the past 12 months?
Becton, Dickinson and Co lowest stock price was $141.82 and its highest was $213.08 in the past 12 months.
What is Becton, Dickinson and Co’s market cap?
Becton, Dickinson and Co’s market cap is $40.68B.
When is Becton, Dickinson and Co’s upcoming earnings report date?
Becton, Dickinson and Co’s upcoming earnings report date is Jul 30, 2026 which is in 64 days.
How were Becton, Dickinson and Co’s earnings last quarter?
Becton, Dickinson and Co released its earnings results on May 07, 2026. The company reported $2.9 earnings per share for the quarter, beating the consensus estimate of $2.778 by $0.122.
Is Becton, Dickinson and Co overvalued?
According to Wall Street analysts Becton, Dickinson and Co’s price is currently Undervalued.
Does Becton, Dickinson and Co pay dividends?
Becton, Dickinson and Co pays a Quarterly dividend of $1.05 which represents an annual dividend yield of 2.13%. See more information on Becton, Dickinson and Co dividends here
What is Becton, Dickinson and Co’s EPS estimate?
Becton, Dickinson and Co’s EPS estimate is 3.13.
How many shares outstanding does Becton, Dickinson and Co have?
Becton, Dickinson and Co has 275,540,440 shares outstanding.
What happened to Becton, Dickinson and Co’s price movement after its last earnings report?
Becton, Dickinson and Co reported an EPS of $2.9 in its last earnings report, beating expectations of $2.778. Following the earnings report the stock price went up 5.872%.
Which hedge fund is a major shareholder of Becton, Dickinson and Co?
Currently, no hedge funds are holding shares in BDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Becton Dickinson Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$182.20 (14.92% Upside)
$182.20 (14.92% Upside)
Blogger Sentiment
Bullish
BDX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 29.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
11.58%
12-Months-Change
Fundamentals
Return on Equity
4.54%
Trailing 12-Months
Asset Growth
-6.67%
Trailing 12-Months
Company Description
Becton, Dickinson and Co
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
BDX Company Deck
BDX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized broad-based operational and commercial execution with revenue growth, margin resilience, strong cash generation and an increased full-year adjusted EPS outlook. Several high-growth platforms delivered double-digit growth and BD Excellence drove meaningful productivity and quicker product launches. Notable near-term headwinds include Alaris' upgrade-cycle comparisons, weaker vaccine demand, China market dynamics, tariff-related margin pressure, a $450 million noncash impairment, and a temporary ship hold following an FDA warning letter. Overall, positive operational momentum and capital returns outweighed the focused and disclosed challenges, giving confidence in the New BD strategy while acknowledging short-term risks.View all BDX earnings summariesBDX Revenue Breakdown
52.45% Medical
23.66% Life Sciences
23.89% Interventional
BDX Stock 12 Month Forecast
Average Price Target
$182.20
▲(14.92% Upside)
Technical Analysis
Ownership Overview
0.17% Insiders
35.95% Mutual Funds
25.03% Other Institutional Investors
11.57% Public Companies and Individual Investors